Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma

Haematologica

Volumn 87, Issue 11, 2002, Pages 1192-1199

  Morabito, Fortunato ^a   Martino, Massimo ^a   Stelitano, Caterina ^a   Oliva, Esther ^a   Kropp, Mariagrazia ^b   Irrera, Giuseppe ^a   Console, Giuseppe ^a   Fujo, Mohamed ^a   Messina, Giuseppe ^a   Molica, Stefano ^b   Callea, Vincenzo ^a   Iacopino, Pasquale ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

Multiple myeloma; Outpatient; Stem cell transplant

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MELPHALAN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; GENDER; HOSPITALIZATION; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; POSTOPERATIVE CARE; STEM CELL TRANSPLANTATION; THROMBOCYTE;

AMBULATORY CARE; FEASIBILITY STUDIES; FEMALE; GRAFT SURVIVAL; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MODELS, ORGANIZATIONAL; MULTIPLE MYELOMA; PATIENT CARE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 6444245572     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91:3-21.
2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336:1657-64.
3. Anonymous. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16:3832-42.
4. Cunningham D, Paz AL, Milan S, Malpas J, Hickish T, Nicolson M, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previous untreated myeloma. J Clin Cncol 1994; 12:759-63.
5. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55-65.
6. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: An Italian multicenter study. Haematologica 2000; 85:52-8.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335:91-7.
8. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Intergroupe Francophone du Myelome. Blood 2002; 99:731-5.
9. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
10. th International Myeloma Workshop. 2001; S15:28.
11. Seregen CM, Sonneveld P, van der Holt P, Vellenga E, Croockewit AJ, Verhoef GE, et al. Intensive versus double intensive therapy in previously untreated multiple myeloma: A prospective randomized phase III study in 450 patients. Proceed VIIIth International Myeloma Workshop. 2001; S17:31.
12. th International Myeloma Workshop. 2001; S16:29-30.
13. Fernand JP, Marolleau JP, Alberti C, Divine M, Leblond V, Macro M, et al. Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD34 enriched ABSC: Preliminary results of a two by two designed randomised trial in 23 young patients with multiple myeloma. Proceed VIIIth International Myeloma Workshop. 2001; P6:147.
14. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastimmobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353-7.
15. Rizzo JD,Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: Cost saving or cost shifting? J Clin Oncol 1999; 17:2811-8.
16. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. Ann Intern Med 1997; 126:600-7.
17. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21:401-7.
18. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998; 16:1179-87.
19. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: A prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
20. Morabito F, Irrera G, Oliva E, Console G, Martino M, Pucci G, et al. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: A single center retrospective abalysis towards outpatient strategy. Bone Marrow Transplant 2001; 28:883-8.
21. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology 2000; 14:171-85.
22. Martino M, Morabito F, Messina G, Irrera G, Pucci G, lacopino P. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996; 81:59-61.
23. Barosi G, Marchetti M, Alessandrino P, Locatelli F, Casula S, Lunghi M, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 1999; 23:719-25.
24. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20:445-50.
25. Peters WP, Ross M, Vrendenburgh JJ, Hussein A, Rubin P, Dukelow K, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; Suppl 7:25-31.
26. Weaver CH, Schwartzberg L, Zhen B, Mangum M, Leff R, Tauer K, et al. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers. Bone Marrow Transplant 1997; 20:753-60.
27. Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T, et al. Outpatient high-dose chemotherapy with autologous stem cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15:11-7.
28. Gluck S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K, et al. High-dose chemotherapy followed by autologous blood cell transplantation: A safe and effective outpatient approach. Bone Marrow Transplant 1997; 20:431-4.
29. Geller RB, Dix SP, Belt RJ, et al. Minimum resource utilization for patients with breast cancer, lymphoma, or multiple myeloma undergoing mobilization and high-dose chemotherapy followed by peripheral blood stem cell transplants as outpatients. Blood 1997; 90:370[abstract].
30. Sharma N, Hendrix L, O'Connell K. Obstacles to performing high-dose therapy with peripheral blood stem cell rescue in the outpatient setting. Blood 1997; Suppl 1:116[abstract].
31. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26:389-95.
32. Rossetti A, Azzara M, Castiglione S, et al. Low incidence of mucositis using a new compound (magnesium chloride) for mucositis prevention after allogeneic BMT and autologous PBSCT. Bone Marrow Transplant 1997; 19 Suppl 1:[abstract 22].
33. Karthaus M, Rosenthal C, Ganser A. Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - Are there new strategies? Bone Marrow Transplant 1999; 24:1095-108.
34. Capelli D, Santini G, De Souza C, Poloni A, Marino G, Montanari M, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study. Br J Haematol 2000; 110:300-7.
35. Kurthaus M, Wolf HH, Kampfe D, Egerer G, Ritter J, Peters G, et al. Ceftriaxone monotherapy in the treatment of lowrisk febrile neutropenia. Chemotherapy 1998; 44:343-54.
36. Serody JS, Berrey MM, Albritton K, O'Brien SM, Capel EP, Bigelow SH, et al. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26:533-8.
37. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20:1295-303.